TCGA-BH-A18L-01A-32R-A12D-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 27
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.500
- E2F_TARGETS+0.490
- MYC_TARGETS_V2+0.460
- MYC_TARGETS_V1+0.420
- INTERFERON_ALPHA_RESPONSE+0.320
- PROTEIN_SECRETION+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.310
- DNA_REPAIR+0.280
- MITOTIC_SPINDLE+0.280
- MTORC1_SIGNALING+0.280
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.620
- COAGULATION-0.430
- ALLOGRAFT_REJECTION-0.400
- APICAL_SURFACE-0.380
- IL6_JAK_STAT3_SIGNALING-0.370
- ANGIOGENESIS-0.360
- NOTCH_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.340
- APICAL_JUNCTION-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3IS-01A-21R-A21D-07 | — | — | 0.888 |
| 2 | TCGA-A8-A092-01A-11R-A00Z-07 | — | B | 0.877 |
| 3 | SRR6013515 | — | cohortA4 | 0.875 |
| 4 | SRR15030853 | — | — | 0.873 |
| 5 | TCGA-44-7669-01A-21R-2066-07 | — | cohortA3 | 0.869 |
| 6 | 2bcd2fcf-9050-4713-aa6b-6cb1419d7ba6 | — | — | 0.857 |
| 7 | BS_H4NXBD2D | Supratentorial Ependymoma | — | 0.854 |
| 8 | TCGA-58-A46K-01A-11R-A24H-07 | — | cohortSQ2 | 0.854 |
| 9 | TCGA-4Z-AA80-01A-11R-A39I-07 | — | — | 0.853 |
| 10 | f354d13d-89ec-4ed6-821d-df3ab230fc91 | — | — | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |